A definitive analysis published on 30 June 2026 by health economists Samuel Cross, Karl Claxton, and Andrew Hill reveals that the UK-US trade deal agreed last December will force the NHS to divert approximately £45 billion from frontline patient services to pay higher prices for American pharmaceuticals by 2036. The same modelling projects 229,000 excess deaths in England as funding is pulled from life-saving treatments, mental health services, and routine care. This is not a distant hypothetical: the diversion of NHS resources has already begun, and its consequences will touch every GP surgery, hospital ward, and patient waiting list across the country.
Unpacking the £45 Billion Threat: How a US-UK Trade Deal Reshapes NHS Funding
The mechanism is straightforward but devastating in scale. Under the trade deal signed with the United States in December 2025, the UK committed to extending pharmaceutical patent protections and altering the way the NHS negotiates drug prices. The practical outcome, according to the analysis published in a leading medical journal on 30 June 2026, is that the NHS will pay substantially more for new medicines, particularly innovative treatments emerging from American pharmaceutical giants. The £45 billion figure represents the cumulative sum diverted from other NHS services between now and 2036, unless the government makes additional funding available: a prospect that looks increasingly unlikely given the current strain on public finances.
To contextualise the scale of this sum, £45 billion could fund the entire annual running cost of NHS England's hospital sector for several months, or cover the nation's GP services many times over. The analysis by Cross, Claxton, and Hill is unambiguous: "Diversion of billions of NHS funding to pay more for new drugs under the UK-US trade deal will harm public health and result in thousands of avoidable deaths." The economists, all based at UK institutions, used established health economics modelling to trace how every pound redirected to inflated drug prices translates into lost care elsewhere.
As of July 2026, the NHS is already navigating severe capacity constraints. The timing of this financial squeeze could scarcely be worse. After three years of dispute, resident doctors in England only accepted a pay deal and ended strike action on 29 June 2026, leaving the health service to tackle a backlog of postponed procedures while simultaneously absorbing the new drug pricing regime. The tension between paying staff fairly and paying pharmaceutical shareholders is no longer theoretical: it is being priced into every NHS trust's budget forecast.
The Ripple Effect: From Drug Costs to Delayed Care and Dire Predictions for UK Patients
The £45 billion diversion does not exist in isolation. Every pound moved into the pharmaceuticals budget is a pound removed from somewhere else: cancer diagnostics, hip replacements, community nursing, or children's mental health services. Health economists describe this as opportunity cost, and in the NHS, where budgets are fixed and demand is infinite, opportunity cost is measured in human suffering.
The starkest projection from the 30 June 2026 analysis is the figure of 229,000 excess deaths in England by 2036. This number arises from modelling how funding reductions across routine and emergency care translate into mortality outcomes. To put that figure in perspective, it exceeds the total number of UK deaths attributed to Covid-19 during the first two years of the pandemic. The researchers are not suggesting these deaths would occur solely from medication shortages; rather, they would accumulate across the system as delayed diagnoses, cancelled procedures, and overstretched services fail to catch treatable conditions in time.
The impact on children's mental health provision is particularly acute and already visible. As of 29 June 2026, over one million children in England have been referred for mental healthcare, with anxiety identified as the primary driver. Waiting times in some regions stretch to years, not months, and every pound diverted from Children and Adolescent Mental Health Services (CAMHS) under the new drug pricing regime will extend those delays further. A child referred today for anxiety support may reach adulthood before receiving a first appointment. The trade deal's pharmaceutical provisions, by locking in higher drug costs, effectively lock out the expansion of these non-pharmaceutical services.
. Simultaneously, the NHS is grappling with profound systemic failures in maternity care. On 30 June 2026, an independent inquiry found "unacceptable racism and discrimination" affecting patient safety in NHS maternity services, with the government pledging urgent action. Dr Bill Kirkup, who resigned from a government-commissioned review into NHS maternity services, claimed that criticism of the "normal birth drive" was removed from a key report. These revelations underscore how financial strain exacerbates existing inequalities: when budgets tighten, the most vulnerable patients, including women from ethnic minority backgrounds who already face worse maternal outcomes, bear the heaviest burden.
The Social Cost: Who Really Pays When the NHS Pays More for Drugs
The £45 billion figure masks a deeply regressive social impact. Wealthier patients with private insurance or the means to pay out-of-pocket can bypass NHS waiting lists entirely, accessing treatments regardless of how public funds are allocated. Low-income households, pensioners on fixed incomes, and communities in deprived areas have no such safety valve. When NHS funding is diverted to cover inflated drug prices, it is these groups who lose access to physiotherapy, talking therapies, joint replacements, and diagnostic scans.
Consider a 68-year-old woman in Middlesbrough with worsening osteoarthritis. She requires a hip replacement to maintain mobility and independence. Under the funding constraints imposed by the trade deal, her local NHS trust may be forced to extend waiting times for elective orthopaedic surgery by several more months. During that wait, her condition deteriorates. She becomes less mobile, more isolated, and increasingly dependent on social care, transferring costs to an equally overstretched local authority. The £45 billion diversion is not just an NHS problem; it cascades into social care, welfare, and the broader economy.
Similarly, women with Premenstrual Ovarian Syndrome (PMOS), a condition affecting millions of UK women that the health watchdog NICE highlighted on 30 June 2026 as still being "under-diagnosed and inconsistently managed," will find it harder to access specialist services as funds are redirected. NICE recommended annual NHS checks for women with PMOS, but the capacity to deliver such proactive, preventative care shrinks with every budget reallocation towards higher drug costs. Preventative health, always the poor relation in funding battles, suffers first.
Political Fallout and the Government's Response
The political implications of the trade deal's health costs are seismic. The NHS is routinely cited by voters as the single most important issue facing the country, and the revelation that a deal negotiated with the previous US administration will drain £45 billion from frontline care has provoked outrage across the political spectrum. Health campaigners have drawn direct comparisons to historical controversies over NHS privatisation, though the mechanism here is more subtle: not an explicit sell-off, but a structural reallocation of public funds towards private pharmaceutical interests.
On 1 July 2026, campaign groups seized on the analysis, with one characterising the deal as likely to "cause more deaths than Covid." While the government has not yet issued a formal response to the £45 billion projection, the political pressure is intensifying. The deal was agreed in December 2025, meaning the current administration inherited its terms, but the decision to honour and implement those terms is an active political choice. Calls for renegotiation, or for emergency supplementary NHS funding to offset the drug price increases, are growing louder by the day.
Adding to the sense of institutional strain, on 25 June 2026, NHS England quietly admitted it cannot prove that its flagship £330 million Palantir data platform delivered the 110,000 extra operations that were used as the primary justification for the contract. The government is now reviewing the deal. The episode has eroded trust in NHS management's ability to steward large contracts and deliver measurable outcomes, precisely the same competencies required to manage the financial fallout from the US trade deal.
News Analysis: A System Under Simultaneous Pressure from Multiple Directions
The £45 billion drug pricing threat does not arrive in isolation. It compounds existing crises. The resident doctors' pay deal on 29 June 2026 ended three years of industrial action, but the cost of the settlement adds further strain to NHS budgets at a time when the trade deal is simultaneously inflating pharmaceutical expenditure. The maternity care scandals demand investment in staffing, training, and oversight. The children's mental health crisis, with its million-plus referral backlog, requires urgent expansion of services, not contraction. Each of these imperatives collides with the pharmaceutical pricing commitments made in the US deal.
What makes the current moment uniquely dangerous for the NHS is the convergence of financial, clinical, and political pressures. The Palantir contract embarrassment has weakened the case for technological efficiency savings as a route out of the funding crisis. The maternity inquiry has exposed deep-seated cultural failures that money alone cannot fix, but which money can certainly worsen if staffing levels are cut. And the sheer scale of the children's mental health backlog means that any funding diversion will have intergenerational consequences, embedding trauma and lost potential into the nation's social fabric for decades.
Privately, senior NHS figures express deep alarm. The health service has survived funding squeezes before, but rarely has it faced such a precisely quantified threat: £45 billion removed from patient care, 229,000 lives lost, and a timeline extending to 2036 that locks in the damage long beyond any single electoral cycle. The analysis by Cross, Claxton, and Hill has shifted the debate from abstract concerns about trade sovereignty to concrete, measurable health outcomes. The numbers are now on the table, and they demand an answer.
What UK Citizens Can Do: Practical Steps to Protect Your Health and Your NHS
While the policy battle plays out in Westminster, there are concrete actions every UK resident can take to safeguard their own health and contribute to the broader defence of the NHS:
- Book overdue check-ups now. If you have been postponing a GP appointment, a dental check, or a routine screening such as a cervical smear or bowel cancer test, schedule it immediately. As waiting lists lengthen, the patients who present early will secure treatment earlier. Do not wait for symptoms to become unmanageable.
- Register with a GP and know your local pharmacy services. Community pharmacists can now treat seven common conditions, including earache, sinusitis, and urinary tract infections, without a GP referral. Using these services reduces pressure on GP surgeries and speeds up your own care.
- Check your eligibility for NHS continuing healthcare or personal health budgets. If you or a family member has long-term health needs, you may be entitled to funded care packages. With budgets tightening, proactive applications are more likely to succeed than reactive ones submitted during a crisis.
- Engage politically. Write to your MP about the £45 billion diversion and the 229,000 excess deaths projection. Reference the analysis by Cross, Claxton, and Hill published on 30 June 2026. Constituency correspondence, particularly when it cites specific, credible data, remains one of the most effective tools for shifting political priorities.
- Support NHS charities and local health advocacy groups. Organisations such as Healthwatch England gather patient feedback and campaign for service improvements. Their influence grows with membership, and local groups often have direct lines to NHS trust decision-makers.
- Stay informed through reliable sources. Follow developments via Baba International for ongoing analysis of the UK-US trade deal's impact on British healthcare, and consult our health articles for practical guidance on navigating the NHS during periods of financial strain.
The £45 billion figure is a projection, not a prophecy. It represents what will happen if the government implements the trade deal's pharmaceutical provisions without providing supplementary funding. The alternative: renegotiation, supplementary budgets, or a combination of both, remains politically and practically possible. But the window for action is narrowing, and the cost of delay is measured in lives.
Baba International Editorial Team
Our editorial team specialises in UK and EU personal finance, health policy, and economic analysis. All content is researched using authoritative sources including the ONS, NHS, Bank of England, ECB, and Eurostat.
Related Reading
- Beyond the Steps: Why a 5-Minute Workday Walk is Your Secret Weapon Against Europe's Sedentary Crisis (and How UK & EU Businesses Can Benefit)
- Beyond the Calories || How Europe's Youth Obesity Crisis is Fueling a Mental Health Tsunami (and What Parents & Policy Makers Can Do)
- Beyond the Beer Garden: || How the EU's Unpreparedness for Extreme Heat is Fuelling a Silent Heart Crisis
- Is the UK Prepared for Extreme Heat? What It Means for Your Health and Bills
Baba International Editorial Team
Our editorial team specialises in UK and EU personal finance, health policy, and economic analysis. All content is researched using authoritative sources including the ONS, NHS, Bank of England, ECB, and Eurostat.
Related Reading
- Beyond the Band-Aid || How the UK's Diabetes Drug Breakthrough is Sparking Hope (and Policy Debates) Across Europe
- Summer Heatwave Survival Guide for UK Households (Health + Energy Costs)
- Is the UK Prepared for Extreme Heat? What It Means for Your Health and Bills
- Beyond the Steps: Why a 5-Minute Workday Walk is Your Secret Weapon Against Europe's Sedentary Crisis (and How UK & EU Businesses Can Benefit)
Frequently Asked Questions
Is the £45 billion figure reliable?
Yes. The £45 billion projection was published on 30 June 2026 by health economists Samuel Cross, Karl Claxton, and Andrew Hill, using established modelling techniques widely accepted in health economics. It represents the cumulative amount diverted from other NHS services by 2036 if the UK-US trade deal's pharmaceutical pricing provisions are implemented without additional funding.
How does the US-UK trade deal increase NHS drug costs?
The deal extends pharmaceutical patent protections and alters the mechanisms by which the NHS negotiates drug prices, effectively reducing the health service's bargaining power. This means the NHS pays higher prices for new medicines, particularly those developed by American pharmaceutical companies, diverting funds from other patient services.
Comments
Post a Comment